
    
      In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner.
      Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done
      with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone
      in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine.
      Finally a two year period of maintenance therapy with 6-mercaptopurine, methotrexate and ATRA
      is performed.
    
  